Last reviewed · How we verify
NCT05162079: ES-REFLUJO
Protocol for the ESREFLUJO Study: Epidemiological Study of Heartburn and Gastroesophageal Reflux in Community Pharmacy
trial in Reflux in 1,200 participants. Status unknown.
1 July 2022
Quick facts
| Lead sponsor | Universidad Miguel Hernandez de Elche |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,200 |
| Start date | 1 March 2022 |
| Primary completion | 1 July 2022 |
| Estimated completion | 1 September 2022 |
Conditions studied
- Reflux — all drugs for Reflux →
Sponsor
Universidad Miguel Hernandez de Elche — full company profile →
Who can join
18 and older, any sex, with Reflux. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Symptoms as heartburn and/or reflux is frequent consultations in community pharmacies, the characterization of them is crucial to provide appropriate patient counseling. To facilitate the assistance work of the community pharmacist and its coordination between different levels of care, a group of experts in Community Pharmacy, Primary Care, and Gastroenterology has recently worked on an algorithm to manage these symptoms. Objective: Analyse the epidemiological characteristics of patients who consult for symptoms of heartburn and/or reflux in Spanish community pharmacies, and evaluate the clinical and humanistic results of the protocolization of a Professional Pharmaceutical Service in said patients. Methods and analysis: The study design consists of a cross-sectional descriptive part, in which the clinical and sociodemographic characteristics of the patients who come to the community pharmacy will be evaluated for consultation derived from heartburn and/or reflux symptoms and a before-after descriptive study in which will evaluate the clinical and humanistic results in patients who come to the pharmacy after receiving pharmaceutical care.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
EsReflux Protocol: Epidemiological Study of Heartburn and Reflux-like Symptoms in Spanish Community Pharmacies.
López-Pintor E, Puig-Moltó M, Lumbreras B. · · 2022 · cited 5× · PMID 36011453 · DOI 10.3390/ijerph19169807 -
Improving Proton-Pump Inhibitor Adherence Intervention Between Primary Care and Community Pharmacies: A Pre-Post Intervention Study.
Puig-Moltó M, Lumbreras B, López-Pintor E. · · 2024 · PMID 39713795 · DOI 10.2147/ppa.s485307
Verify or expand the search:
- PubMed search for NCT05162079
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Reflux
Currently open trials in the same condition.
- NCT06999577 — The Mechanism Versus PPI Trial · Phase 4 · recruiting
- NCT05629143 — Primary carE PPi dEprescRibing Trial · Phase 4 · active not recruiting
Other Universidad Miguel Hernandez de Elche trials
Trials by the same sponsor.
- NCT07498569 — Effects of Percutaneous Electrical Stimulation in Patients With Chronic Supraspinatus Tendinopathy · NA · not yet recruiting
- NCT07237971 — Cocreating Action to Improve Rationality in the Health System · NA · recruiting
- NCT07146789 — Home-based Graded Repetitive Arm Supplementary Program for Quality of Life and Functional Upper Limb Recovery · NA · recruiting
- NCT06889389 — Effects of Education and Exercise on Pain, Psychosocial Factors, and Upper Limb Function in Non-specific Neck Pain. · NA · recruiting
- NCT07192835 — Effect of Fruit Elicitation With Melatonin on Human Health · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05162079 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universidad Miguel Hernandez de Elche
- Last refreshed: 17 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162079.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing